No clear benefit from lirilumab, nivolumab combination

An immuno-oncology combination that had initially produced an objective response in a Phase 1/2 trial of patients with head and neck cancer, failed to show benefit in an extended patient population, Innate Pharma SA announced on 22 November.

Full text available to subscribers only. Click here for information on subscribing to MedNous.